Royalty Pharma plc (RPRX) | Stock Overview & Key Data
Royalty Pharma plc Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $56.50 on June 15, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Royalty Pharma plc
RPRX
|
29.43B Large-cap | -1.08% | 2.69% | 17.72% | 40.85% | 39.66% | 57.49% | 72.01% | 24.65% | 11.98% | 11.98% | 11.98% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Alnylam
ALNY
|
41.87B Large-cap | -1.49% | 0.29% | -9.76% | -26.49% | -28.08% | -8.16% | 40.32% | 59.90% | 405.36% | 3,032.34% | 1,907.45% |
|
Insmed
INSM
|
31.05B Large-cap | 3.49% | -10.70% | -32.60% | -50.51% | -44.98% | -0.89% | 389.25% | 236.25% | 934.36% | 717.46% | 614.23% |
|
Revolution Medicines
RVMD
|
28.61B Large-cap | 7.79% | 9.89% | 61.68% | 102.61% | 102.56% | 279.08% | 524.98% | 353.09% | 443.52% | 443.52% | 443.52% |
Ownership & Short Interest
Calculate Your Royalty Pharma plc Investment Returns
Long-Term Investment Performance Analysis
Royalty Pharma plc stock price in Jun 2020 was $49.00, A $1,000.00 lump sum investment in Royalty Pharma plc made 6 years ago would be worth approximately $1,107.55 today, representing a positive return of 10.76%. This translates to an annualized return (CAGR) of 1.72%.
6 Years Investment Scenario (Jun 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is RPRX's 52-week high and low?
- In the last 52 weeks, Royalty Pharma plc reached a high of $56.50 (on June 8, 2026) and a low of $34.08 (on September 8, 2025).
- What is the market cap and P/E ratio for RPRX?
- Curious about Royalty Pharma plc's size and valuation? Its market capitalization stands at 29.43B. When it comes to valuation, the P/E ratio (trailing twelve months) is 27.89, and the forward P/E (looking ahead) is 8.98.
- Does RPRX pay dividends? If so, what's the yield?
- Yes, Royalty Pharma plc is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.76%, and the company has paid an average of $0.92 per share annually over the past 3 years.
- Who are Royalty Pharma plc's main competitors or similar companies to consider before investing?
When looking at Royalty Pharma plc, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Alnylam
ALNY41.87B Healthcare Biotechnology -8.16% 40.32% Insmed
INSM31.05B Healthcare Biotechnology -0.89% 389.25% Revolution Medicines
RVMD28.61B Healthcare Biotechnology 279.08% 524.98% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Royalty Pharma plc? (e.g., ROE, Debt/Equity)
- To get a sense of Royalty Pharma plc's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.20%, the Debt to Equity ratio from the most recent quarter is 92.33, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for RPRX?
- Looking at Royalty Pharma plc's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.80%, and quarterly earnings saw a YoY growth of 2.90%.
- How much of RPRX stock is held by insiders and institutions?
- Wondering who owns Royalty Pharma plc stock? Company insiders (like executives and directors) hold about 7.12% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 84.60%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.